CRONNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Cronos Group Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.25+0.04 (+1.25%)
Close on Oct 19, 2026
- Market cap
- $1.22B
- P/E (TTM)
- 16.3
- Dividend yield
- –
Cronos Group Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cannabis flower | $39.21M | $33.73M | $33.75M | $26.36M | $25.03M | $23.34M | $23.40M | $26.33M | $20.66M | $17.53M | $17.51M | $17.41M | 74.0% | +56.7% |
| Cannabis extracts | $13.77M | $11.46M | $10.77M | $9.96M | $8.36M | $8.61M | $6.59M | $7.79M | $7.06M | $7.73M | $6.07M | $7.27M | 26.0% | +64.8% |
| Other | $19.00K | $19.00K | $18.00K | $13.00K | $70.00K | $310.00K | $315.00K | $147.00K | $37.00K | $36.00K | $327.00K | $128.00K | 0.0% | -72.9% |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Canada | $28.71M | $25.35M | $27.92M | $23.13M | $19.15M | $20.13M | $19.66M | $24.07M | $19.84M | $18.87M | $17.94M | $18.74M | 54.2% | +49.9% |
| Israel | $15.02M | $14.15M | $11.84M | $11.35M | $9.38M | $9.23M | $7.80M | $7.26M | $6.89M | $6.42M | $4.97M | $5.67M | 28.3% | +60.2% |
| Other countries | $9.28M | $5.71M | $4.78M | $1.85M | $4.93M | $2.90M | $2.84M | $2.94M | $1.03M | $0 | $1.01M | $399.00K | 17.5% | +88.3% |
From the segment and revenue-disaggregation notes of Cronos's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.